Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
05/2011
05/05/2011WO2011053522A1 Tertiary amide orexin receptor antagonists
05/05/2011WO2011053519A1 Diuretics
05/05/2011WO2011053518A1 Methods of synthesis and purification of heteroaryl compounds
05/05/2011WO2011053511A1 Heteroaryl substituted arylindenopyrimidines and their use as highly selective adenosine a2a receptor antagonists
05/05/2011WO2011053510A1 Heterocyclyl substituted arylindenopy-rimidines and their use as highly selective adenosine a2a receptor antagonists
05/05/2011WO2011053509A1 Aryl substituted arylindenopyrimidines and their use as highly selective adenosine a2a receptor antagonists
05/05/2011WO2011053508A1 ALKYL SUBSTITUTED ARYLINDENOPYRIMIDINES AND THEIR USE AS HIGHLY SELECTIVE ADENOSINE A2a RECEPTOR ANTAGONISTS
05/05/2011WO2011053507A1 2-amino-9-[4-(4-methoxy-phenoxy) - piperid in -1-yl] -4-phenyl-indeno [1,2-d] pyrimidin -5 -one and its use as a highly selective adenosine a2a receptor antagonist
05/05/2011WO2011053504A1 Solid pharmaceutical compositions containing an integrase inhibitor
05/05/2011WO2011053476A1 Imidazopyridines as a novel scaffold for multi-targeted kinase inhibition
05/05/2011WO2011053468A1 Amino-benzoic acid derivatives for use in the treatment of dihydrogenase-related disorders
05/05/2011WO2011053466A1 Ite for cancer intervention and eradication
05/05/2011WO2011053292A1 Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands
05/05/2011WO2011053172A2 Drug for treating hiv/aids infections and the loss of sexual desire, method for preparing same and use thereof.
05/05/2011WO2011053144A2 Methods and compositions for dysferlin exon-skipping
05/05/2011WO2011053090A2 Novel 2, 4-pyrimidine derivatives and use thereof
05/05/2011WO2011053048A2 Novel vascular leak inhibitor
05/05/2011WO2011053003A2 Gastric-retentive sustained release formulation containing pregabalin, polyethyleneoxide and pva-peg graft copolymer
05/05/2011WO2011052968A2 Composition for preventing or treating degenerative neurological disorder, containing oleanonic acid
05/05/2011WO2011052950A2 Pharmaceutical composition comprising indole compound
05/05/2011WO2011052940A2 Process for preparing clopidogrel hydrogensulfate form i
05/05/2011WO2011052923A2 Novel 1,6-disubstituted indole compounds as protein kinase inhibitors
05/05/2011WO2011052919A2 Novel alpha-galactosylceramide derivatives, pharmaceutically acceptable salts thereof, method for preparing same, and pharmaceutical composition for an immune adjuvant, containing the derivatives as active ingredients
05/05/2011WO2011052888A2 (3-fluoro-2-hydroxy)propyl-functionalized aryl derivatives or pharmaceutically acceptable salts thereof, method for preparing same, and pharmaceutical composition containing same as active ingredients for the diagnosis or treatment of neurodegenerative brain diseases
05/05/2011WO2011052884A2 Sustained release tablet containing theobromine
05/05/2011WO2011052765A1 Alleviator for renal disorders caused by administration of platinum-containing drug
05/05/2011WO2011052759A1 Novel nitroxyl radical compound and process for production thereof
05/05/2011WO2011052756A1 Novel 3-hydroxy-5-arylisoxazole derivative
05/05/2011WO2011052750A1 Anticancer agent sensitivity-determining marker
05/05/2011WO2011052749A1 Method for determination of sensitivity to anti-cancer agent
05/05/2011WO2011052748A1 Method for determining sensitivity to an anticancer agent
05/05/2011WO2011052715A1 Modified double-stranded polynucleotide
05/05/2011WO2011052706A1 Dry powder inhaler of tranilast having high solubility
05/05/2011WO2011052628A1 Angiogenesis promoter
05/05/2011WO2011052554A1 Novel 5-fluorouracil derivative
05/05/2011WO2011052519A1 Benzazepine compound
05/05/2011WO2011052500A1 Wax stable formulation
05/05/2011WO2011052499A1 Pharmaceutical composition having improved storage stability
05/05/2011WO2011052436A1 Bridged artificial nucleoside and nucleotide
05/05/2011WO2011051974A1 Metformin and a-amino acids
05/05/2011WO2011051967A2 Pharmaceutical compositions comprising mycophenolate and processes for preparing thereof
05/05/2011WO2011051966A2 Pharmaceutical compositions for the treatment/prophylaxis of non-alcoholic fatty liver disease
05/05/2011WO2011051961A1 Compounds for the treatment of dyslipidemia and related diseases
05/05/2011WO2011051960A2 Process for the preparation of rapamycin derivatives
05/05/2011WO2011051950A1 9-aminoacridine derivatives, their preparation and uses
05/05/2011WO2011051945A1 Therapeutic uses of oligomeric and polymeric monoterpenes
05/05/2011WO2011051938A1 Composition for treatment of thyroid cancer with fts and analogs thereof
05/05/2011WO2011051900A1 Preparation comprising amino acids and plants and its activity in the alcohol detoxification
05/05/2011WO2011051899A1 A synergistic composition of (-)-hydroxycitric acid with monoterpene and a method to enhance satiety
05/05/2011WO2011051898A1 Use of celivarone for preparing a medicament for the treatment of patients with arrhythmia and having an increase of creatinine level due to celivarone administration
05/05/2011WO2011051894A1 Novel antitumoral use of cabazitaxel
05/05/2011WO2011051864A1 Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
05/05/2011WO2011051858A1 Imidazole derivatives as casein kinase inhibitors
05/05/2011WO2011051853A1 Manufacturing process for preparing enaniomerically pure 8- aryloctanoic acid derivatives such as aliskiren
05/05/2011WO2011051814A1 Novel crystalline forms of (3r,6r) -3- (2, 3 -dihydro- 1h- inden- 2 -yl) - 1 - [ (1r) - 1 - (2, 6 - dimethyl - 3 - pyridinyl) - 2 - (4 -morpholinyl) -2-oxoethyl] -6- [(1s) - 1 -methylpropyl] -2,5- piperazinedione
05/05/2011WO2011051813A1 Compositions and methods for treating dermatological conditions
05/05/2011WO2011051742A1 Preparation comprising amino acids and plants and its activity in the alcohol detoxification
05/05/2011WO2011051704A1 Chromenone derivatives with anti-tumour activity
05/05/2011WO2011051673A1 Aminothiazole derivatives useful as klk1 inhibitors
05/05/2011WO2011051672A1 Azaindole derivatives
05/05/2011WO2011051671A1 Aminopyridine derivatives as kallikrein inhibitors
05/05/2011WO2011051665A1 Anti-cancer composition comprising alginate
05/05/2011WO2011051634A1 Use of ferroquine in the treatment or prevention of malaria
05/05/2011WO2011051540A1 Androgen receptor modulating compounds
05/05/2011WO2011051535A1 Bis(aralkyl)amino and six membered (hetero)aromatic system derivatives and the use thereof in the treatment of neurodegenerative pathological conditions, including alzheimer's disease
05/05/2011WO2011051527A1 1,8-naphthyridine-derived compounds and the use thereof in the treatment of neurodegenerative diseases
05/05/2011WO2011051520A1 Triterpenic saponins from the crocus sativus corm as an adjuvant in protein vaccine formulations
05/05/2011WO2011051483A1 Pterostilbene (pter) for use in the prevention and/or treatment of skin diseases, damages or injures
05/05/2011WO2011051478A1 Novel oxime derivatives and their use as allosteric modulators of metabotropic glutamate receptors
05/05/2011WO2011051452A1 N-containing heteroaryl derivatives as jak3 kinase inhibitors
05/05/2011WO2011051425A1 N-oxide of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea
05/05/2011WO2011051423A1 Treatment or prophylaxis of dementia, neurodegenerative disorders, schizophrenia, adhd, somnolence or epilepsy
05/05/2011WO2011051384A1 Process for making crystalline form a of linezolid
05/05/2011WO2011051375A1 2-aryl-propionamide derivatives useful as bradykinin receptor antagonists and pharmaceutical compositions containing them
05/05/2011WO2011051342A1 IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS
05/05/2011WO2011051282A1 (1,1, 1,3, 3, 3-hexafluoro-2-hydroxypropan-2-yl) phenyl derivatives, pharmaceutical compositions thereof and their use for the treatment of atherosclerosis
05/05/2011WO2011051270A1 Method of treatment
05/05/2011WO2011051269A1 Method of treatment
05/05/2011WO2011051264A2 Method of treatment
05/05/2011WO2011051201A1 Positive allosteric modulators (pam)
05/05/2011WO2011051165A1 Substituted 3-phenylpropionic acids and the use thereof
05/05/2011WO2011051159A1 Avermectins and milbemycins for the treatment of flavivirus infections
05/05/2011WO2011050961A1 Composition comprising fesoterodine and fiber
05/05/2011WO2011050947A2 Tape, in particular, adhesive tape, for the treatment of skin disorders comprising at least one hyperkeratosis inhibitor and/or at least one keratinolytic agent
05/05/2011WO2011050944A1 Formulations containing celecoxib
05/05/2011WO2011050871A1 Use of menthyl ethers as anti-bacterial, anti-mycotic or anti-viral active substances
05/05/2011WO2011050864A1 New compounds for the treatment of diseases related to protein misfolding
05/05/2011WO2011050826A1 Process for making crystalline form a of linezolid
05/05/2011WO2011050742A1 New crystalline forms of agomelatine and preparation methods thereof
05/05/2011WO2011050739A1 Submicro emulsion of paclitaxel using steroid complex as intermediate carrier
05/05/2011WO2011050735A1 Paclitaxel/steroidal complex
05/05/2011WO2011050728A1 Stable composition of rasagiline
05/05/2011WO2011050684A1 Pharmaceutical composition for treating tumor
05/05/2011WO2011050638A1 A crystalline form of bimatoprost, preparation method and use thereof
05/05/2011WO2011050590A1 Polymorph of 3-(substituteddihydroisoindolinone-2-yl)-2,6-dioxopiperidine, and pharmaceutical compositions thereof
05/05/2011WO2011050575A1 Hydroxy-substituted gold(iii) porphyrin complexes as histone deacetylase inhibitors
05/05/2011WO2011050574A1 Pharmaceutical composition containing cyclometalated n-heterocyclic carbene complexes for cancer treatment
05/05/2011WO2011050481A1 New eremophilane sesquiterpene lactones from senecio jacobaea
05/05/2011WO2011050474A1 Concentrated therapeutic phospholipid compositions
05/05/2011WO2011050459A1 Methods and uses for treating hepatic ischemia and reperfusion injury